b'Source: Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2023 Feb 28;38(3):532-541. doi: 10.1093/ndt/gfac283. PMID: 36264305; PMCID: PMC9976771.prescription compared with white patients (adjusteddifferencesexistandhowtheyaffectclinical odds ratio, 0.72 [95% CI, 0.71-0.74] for SGLT2i andoutcomes.0.64 [95% CI, 0.63-0.66] for GLP-1 RA), the study1 Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers authors pointed out. Patients of Hispanic or Latinoto implementing new guideline-directed therapies for chronic kidney ethnicity had significantly lower odds of prescrip- disease. Nephrol Dial Transplant. 2023 Feb 28;38(3):532-541. doi: tion (0.90 [95% CI, 0.88-0.93] for SGLT2i and 0.8810.1093/ndt/gfac283. PMID: 36264305; PMCID: PMC9976771. [95% CI, 0.85-0.91] for GLP-1 RA) compared with2 Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. As-non-Hispanic or Latino patients. sociation of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in Theauthorscalledforfurtherresearchtobet- the Veterans Health Administration System. JAMA. 2022;328(9):861terunderstandwhythoseunderlyingprescribing871. doi:10.1001/jama.2022.13885 93'